IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.05
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.06

22 Nov
2024

0.006

OPEN

$0.05

11.11%

HIGH

$0.06

2,263,828

LOW

$0.05

TARGET
$0.16 166.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.0 - 0.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.3 M
Book Value Per Share xxxxxxxxxxxxxxx2.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.8 M
Net Profit Margin xxxxxxxxxxxxxxx-191.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-38.95 %
Return on Invested Capital xxxxxxxxxxxxxxx-38.21 %
Return on Assets xxxxxxxxxxxxxxx-34.20 %
Return on Equity xxxxxxxxxxxxxxx-38.95 %
Return on Total Capital xxxxxxxxxxxxxxx-46.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx3.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.1 M
Capex % of Sales xxxxxxxxxxxxxxx30.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

23/10/2024

1

Speculative Buy.

$0.13

116.67%

Ord Minnett notes ImpediMed reported 1Q25 results which were essentially in line with expectations.

The broker observes a rise in US SOZO sales of 28 compared to 22 in 4Q24 and growth of 21% in annual recurring revenue on a year earlier.

As the company's cash burn recedes, Ord Minnett remains positive on the stock's outlook as payor coverage in the US continues to expand.

.Buy rating retained. Target price slips to 13c from 15c.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.70 cents.
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.30 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

04/09/2024

1

Overweight

$0.17

183.33%

Wilsons characterises FY24 as a "reset year" for ImpediMed, noting the stock is trading at a material discount to fundamentals because the market doubts the new team can derive enough revenue in the short term to avoid raising equity.

The broker acknowledges it looks "tight" by FY26 based on current revenue and growth performance, yet assesses several deals will become larger and the company will reprice the back book of legacy contracts as renewals.

Overweight retained. Target edges down to $0.17 from $0.18.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.80 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Australian Broker Call *Extra* Edition – Oct 28, 2024

Oct 28 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 26, 2024

Sep 26 2024 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 13-09-24

Sep 13 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Sep 13, 2024

Sep 13 2024 - Daily Market Reports
5
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps